Pharma, biotech and radiopharma news
Drug discovery, major trial results, mergers, partnerships and new capacity across the US and Canada. Sources on every story.
SELLAS Vaccine Cuts Death Risk 41% in Phase 3 Leukemia Trial
In a 126-patient phase 3 AML trial, median survival was 24.0 months on the SELLAS vaccine GPS versus 14.7 months on best available treatment.
Lilly's 15th Buyout of 2026 Is Up to $1.5B for Blood Cancer Startup
Lilly agreed to buy Calytrix Bio, a Massachusetts startup with an early antibody for two rare blood cancers, for up to $1.5 billion in cash.
FDA Approves Roche Pill After 62% Cut in Progression or Death Risk
The FDA approved Roche's oral drug Wilserdly with everolimus for advanced breast cancer with an ESR1 mutation, four weeks ahead of its goal date.
Cellectis to Cut Up to 70% of Staff After Dropping Its CAR-T Trials
Cellectis plans to cut up to 70% of staff over 2026 and 2027 as it stops its own CAR-T trials and shifts to in vivo gene editing for lipid disorders.
FDA Turns Down Summit Lung Cancer Drug Tied to $2B AstraZeneca Deal
The FDA declined to approve Summit's ivonescimab in EGFR-mutated lung cancer because its phase 3 trial did not show a significant overall survival gain.
Lilly's $3.5B Pennsylvania Obesity Drug Site to Create 850 Jobs
Lilly broke ground on a $3.5 billion Lehigh Valley plant that will make injectables like retatrutide. It expects 850 jobs and an opening by 2031.
Moffitt Coalition Gets $47.3M to Build Florida Radiopharma Hub
A Moffitt-led group won $47.3 million in US funding for a Tampa Bay radiopharma hub, including $16.9 million toward an isotope and therapy plant.
Crinetics to Cut 78 Jobs Under Vertex After $10B Buyout
Crinetics, now owned by Vertex, will let go of 78 staff on Jan. 4, 2027, mostly in corporate roles. It disclosed the cuts about two months after the $10B deal closed.
Blackstone to Fund Up to $1.5B of Pfizer's Obesity Shot Development
Blackstone will cover up to $1.5 billion of berobenatide development costs through 2028 in return for milestone payments, while Pfizer keeps full ownership of the drug.
Novartis Reports 9 Tumours in Zolgensma Patients as FDA Investigates
Novartis says nine tumours have been reported in Zolgensma patients. The FDA says testing found the gene therapy's vector DNA in two of them and is weighing next steps.
Beam's Base-Edited Sickle Cell Therapy Meets 12-Month Trial Goal
Beam Therapeutics says risto-cel met its main goal of 12 months free of severe pain crises in sickle cell disease, and plans a US filing as early as year end.
FDA Approves Merck KGaA Tumour Pill After 56% Respond in Trial
The FDA approved Merck KGaA's pimicotinib, sold as Pimjetmi, for TGCT. In a 94-patient trial, 56% on the drug responded at week 25, compared with 3% on placebo.
Argenx to Pay $550M Upfront in Up to $1.15B Peptide Biotech Buyout
Argenx will pay $550 million in cash upfront, and up to $595 million more in milestones, for Santa Cruz peptide biotech Unnatural Products.
Lantheus to Sell New Jersey Radiopharma Plant and CDMO to PharmaLogic
PharmaLogic agreed to buy Lantheus's contract manufacturing business and its Springfield, New Jersey site, and will make Lantheus's lutetium Lu 177 dotatate.
FDA Approves Bayer's Sunharbo After It Cut Stroke Risk 26%
The FDA approved Bayer's Sunharbo for adults after a recent non-cardioembolic ischemic stroke or high-risk TIA. It is the first Factor XIa inhibitor approved in the US.
Pfizer Plans $650M Groton Plant to Make Drugs for Its Own Trials
Pfizer will spend USD 650 million over five years on a 220,000 square foot Groton, Connecticut site to make drugs for its clinical trials.
Vir's Hepatitis Delta Combo Leaves Virus Undetectable in 79%
Vir's monthly elebsiran and tobevibart regimen met its phase 3 goal in hepatitis delta, with 44% reaching the combined endpoint at week 48.
Boehringer Pledges $358M, Up to $7B More, for 6 Sino Cancer Programs
Boehringer Ingelheim takes options on six preclinical ADC and T-cell engager programs from SBP Group for US$358 million near term and up to US$7 billion in milestones.
Agios Cuts Over 100 R&D Roles While FDA Delays Sickle Cell Ruling
Agios will cut more than 100 R&D roles, over 35% of its R&D staff, as the FDA pushes its sickle cell decision on mitapivat to Feb. 1, 2027.
Rhythm Shares Jump 28% on Reported AstraZeneca Takeover Bid
Rhythm shares closed up 28% after a report of an AstraZeneca offer. Reuters later put the non-binding bid at up to $134 a share. Neither firm has confirmed it.